TABLE 1.

Summary of clinically relevant NS3 amino acid changes associated with reduced susceptibility to HCV protease inhibitors (11)

Drug	Substitution(s)a detected in patients with virologic failure at NS3 amino acid position:
	36	43	54	55	80	122	132	155	156	158	168	170	175
Faldaprevir								K, Q	T		V, E, A, N, T
Simeprevir					K, R	A, G, R		K, Q			V, E, A, H	T
Vaniprevir		S						K, G, T			V, Y, G, A
Boceprevir	M, A		A, S, C, G	A				K, T	S, T, V	I	N	A, T	L
Telaprevir	M, A, L, G, I		A, S				V	K, T, G, M	S, T, V, F, N		N

^aUnderlined letters indicate variants reported in ≥10% of patients failing treatment in phase 2 or phase 3 studies (others are reported in <10% of patients failing treatment in phase 2 or phase 3 studies).